Identification of a conserved neutralizing epitope in Seneca Valley virus VP2 protein: new insight for epitope vaccine designment

Background Seneca Valley virus (SVV) is a picornavirus that causes vesicular disease in swine. Clinical characteristics of the disease are similar to common viral diseases such as foot-and-mouth disease virus, porcine vesicular disease virus, and vesicular stomatitis virus, which can cause vesicles in the nose or hoof of pigs. Therefore, developing tools for detecting SVV infection is critical and urgent. Methods The neutralizing antibodies were produced to detect the neutralizing epitope. Results Five SVV neutralizing monoclonal antibodies (mAb), named 2C8, 3E4, 4C3, 6D7, and 7C11, were generated by immunizing mouses with ultra-purified SVV-LNSY01-2017. All five monoclonal antibodies exhibited high neutralizing titers to SVV. The epitopes targeted by these mAbs were further identified by peptide scanning using GST fusion peptides. The peptide (153)QELNEE(158) is defined as the smallest linear neutralizing epitope. The antibodies showed no reactivity to VP2 single mutants E157A. Furthermore, the antibodies showed no neutralizing activity with the recombinant virus (SVV-E157A). Conclusions The five monoclonal antibodies and identified epitopes may contribute to further research on the structure and function of VP2 and the development of diagnostic methods for detecting different SVV strains. Additionally, the epitope recognized by monoclonal antibodies against VP2 protein may provide insights for novel SVV vaccines and oncolytic viruses development.

Automated summary

Researchers have produced five monoclonal antibodies that can detect SVV infection, and these antibodies exhibit high neutralizing titers to SVV. The smallest linear neutralizing epitope (153)QELNEE(158) has been identified. These monoclonal antibodies and identified epitopes are important for further research on VP2 structure and function, as well as the development of diagnostic methods for different SVV strains. Moreover, the epitope recognized by these monoclonal antibodies against VP2 protein may provide insights for the development of novel SVV vaccines and oncolytic viruses.